Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema

Next Previous
Trial Profile

Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EO 2002 (Primary) ; Ripasudil
  • Indications Corneal disorders
  • Focus Adverse reactions

Most Recent Events

  • 08 Dec 2025 Planned End Date changed from 1 Dec 2025 to 9 Dec 2025.
  • 08 Dec 2025 Planned primary completion date changed from 30 Jul 2025 to 9 Dec 2025.
  • 02 Aug 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top